Ergotyl

Quick links to important sections

Ergotyl

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ergotyl

Here is a quick overview of the medicine containing Ergometrine Maleate and Methylergometrine Maleate.

Property Description
Active ingredients Ergometrine Maleate, Methylergometrine Maleate
Forms Oral tablets, Solution for injection (Ampoules)
Pharmacological class Oxytocic agent (Uterotonic agent)
General purpose To induce sustained uterine muscle contraction
Origin Semi-synthetic Ergot alkaloid derivative

Overview: What Type of Medicine is Ergotyl?

Ergotyl is a semi-synthetic pharmaceutical combination product classified scientifically as a potent oxytocic agent, commonly known as a uterotonic agent. Its high-level function is to promote strong, sustained contraction of the uterine smooth muscle. The general purpose of this specific pharmacological action is to help the uterus achieve a necessary, firm physiological state following childbirth or other specific procedures in obstetrics and gynecology. The medicine is recognized for its sustained effect, a characteristic utilized in managing postpartum physiological needs. The combination is used to achieve powerful uterine tonus, distinguishing it from agents that primarily provide only rapid, transient effects.

Composition, Origin, and Available Forms

The core of the medicine is a fixed-dose combination product containing two closely related active ingredients: Ergometrine Maleate and Methylergometrine Maleate. These substances are classified as semi-synthetic derivatives because their structure originates from naturally occurring ergot alkaloids that are subsequently modified for medicinal use. The sustained uterine action is a key property of these compounds, which function as spasmolytic agents targeting the uterus. This means the components work to promote a strong, controlled spasm of the uterine muscle. Due to varied clinical needs, the medicine is prepared in multiple dosage forms, including oral tablets and a sterile solution for injection (ampoules). This availability in both quick-acting parenteral and maintenance oral forms is a critical differentiating feature, allowing for flexibility in clinical approach.

What side effects are possible with Ergotyl?

Possible Side Effects and Safety Information (Ergotyl)

This information is based strictly on governmental regulatory documents detailing the drug’s official safety profile.

Serious Adverse Reactions

The most significant safety concern is the potential for vasospasm, which is severe narrowing of blood vessels. This rare but serious condition, often called ergotism, can restrict blood flow to the heart (leading to angina or Myocardial Infarction), the extremities, or the brain (leading to Stroke). Patients are advised to seek immediate medical attention if they experience symptoms of reduced blood flow, such as cold, numb, or painful extremities.

Other serious documented reactions include severe hypertension and, rarely, fibrotic complications (pleuropulmonary or retroperitoneal fibrosis) associated with prolonged use.

Common Adverse Reactions

Adverse reactions that occur frequently, typically affecting the Gastrointestinal and Nervous Systems, include:

  • Nausea
  • Vomiting
  • Dizziness
  • Paresthesia (tingling or numbness)

Safety Restrictions and Contraindications

Ergotyl is strictly contraindicated (must not be used) in certain situations due to the high risk of serious adverse events:

  • Concomitant Use with Strong CYP3A4 Inhibitors: Using this medicine with certain drugs (like some antibiotics, HIV protease inhibitors, or antifungal agents) is forbidden, as it significantly raises the risk of severe vasospasm.
  • Cardiovascular Disease: It is contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or peripheral arterial disease.
  • Pregnancy: It must not be used during pregnancy due to the risk of harm to the fetus.

Dose- and Exposure-Related Risks

Official labeling documents that excessive or frequent use of this medicine may lead to Medication Overuse Headache (MOH), a safety pattern where the medication itself causes the headache to persist or worsen.

Overdose and Emergency Response

The official regulatory profile for Ergotyl overdose defines specific clinical manifestations and mandates immediate emergency action. Documented initial manifestations may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain. Other systemic and sensory effects recognized in official labeling are numbness, tingling of the extremities, and hypothermia. A recognized physiological sign is an initial rise in blood pressure, which can progress in severe cases.

Life-threatening outcomes documented in prescribing information include central nervous system depression leading to convulsions and coma, as well as severe respiratory depression and dangerous peripheral vasospasm. Due to the risk of these severe manifestations, individuals must contact emergency services immediately or call a Poison Control Center if an overdose is suspected, especially if the person has collapsed, is having trouble breathing, or cannot be awakened.

Treatment is officially described as symptomatic and supportive. There is no specific antidote established in the labeling. Management procedures may involve accelerating the removal of the drug through methods like gastric lavage and ensuring the maintenance of adequate pulmonary ventilation. Other supportive measures include correcting hypotension with pressor drugs and controlling seizures with standard anticonvulsant agents. Accidental exposure in newborn infants is documented to result in severe symptoms, including respiratory depression and oliguria.

Therapeutic Uses of Ergotyl

Ergotyl (Ergometrine Maleate/Methylergometrine Maleate) is used in clinical settings that involve acute or unstable symptom patterns requiring sustained uterine contraction following delivery or certain gynecological procedures. Its use is applied in addressing conditions and symptom patterns associated with inadequate uterine muscle function.


This medication is commonly used to manage and prevent excessive uterine blood loss and to address uterine atony, the symptom where the uterine muscle lacks the necessary firmness. It is also considered relevant for supporting delayed uterine recovery (subinvolution) during the weeks following childbirth. These indications are applied across domains where additional symptomatic support is needed, primarily in obstetrics and gynecology. The primary therapeutic purpose is to help ease the overall symptom load by supporting the reduction of excessive blood loss, assisting with stability during periods of heightened symptoms.

“This type of agent is relevant for managing symptoms related to increased muscular activity and assists in maintaining functional stability.”


Quick Fact: Supportive Relief for Bleeding Symptoms. Ergotyl generally provides direct support for symptoms related to heightened physiological activity, specifically symptoms related to a lack of uterine tone. It is intended to assist with maintaining functional stability in the context of the condition, which may provide supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility for Ergotyl

Regulatory agencies define strict eligibility criteria for Ergotyl, an ergot derivative, primarily based on avoiding risks associated with its vasoconstrictive properties.

Populations Who Must Not Use Ergotyl (Contraindications)

Classification Condition or Population
Cardiovascular Risk Patients with uncontrolled hypertension or vascular disease (coronary or peripheral).
Physiological State Women who are pregnant (due to potent uterotonic effects) and those with toxemia of pregnancy (e.g., pre-eclampsia, eclampsia).
Allergy Known hypersensitivity to Ergotyl or any other ergot derivative.

Populations Requiring Special Caution

  • Organ Impairment: Use requires special caution and monitoring in patients with hepatic or renal impairment, as drug clearance may be reduced.
  • Sepsis: Patients with sepsis or severe infection should use this medication with caution.
  • Breastfeeding: Use is generally not recommended or limited, as small amounts may pass into breast milk.

Age-Related Eligibility

Use is formally not established for the pediatric population (under 18 years of age) due to insufficient safety and efficacy data. Its use is restricted to adults for specific, short-term obstetrical indications.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation identifies specific medicinal and non-medicinal substances that interact with the active ingredients in Ergotyl (Ergometrine Maleate and Methylergometrine Maleate).


Contraindicated Combinations

Co-administration with potent CYP 3A4 inhibitors is formally prohibited due to the risk of severely increased exposure and toxicity, including acute vasospasm. Examples include certain macrolide antibiotics (e.g., Clarithromycin) and azole antifungals (e.g., Ketoconazole). The co-use of triptans (5HT1B/1D receptor agonists) is also contraindicated due to the risk of additive vasoconstriction.


Pharmacodynamic and Metabolic Cautions

Interaction Type Regulatory Caution / Effect
Pharmacodynamic Vasoconstrictors and sympathomimetics may enhance vasoconstrictive effects, potentially leading to severe postpartum hypertension. Prostaglandins and analogues may potentiate the uterotonic action.
Metabolic CYP 3A4 inducers (e.g., Rifampicin) may reduce the drug's efficacy by increasing its clearance.

Other Documented Interactions

Interactions are documented with non-medicinal products that affect the primary interaction domains. Grapefruit juice is noted as a CYP 3A4 inhibitor that may increase drug levels, and tobacco smoking may enhance vasoconstriction. Furthermore, specific caution is required in patients with hepatic or renal impairment, as reduced clearance in these populations can heighten the risk associated with all drug interactions.

Mechanism of Action

Ergotyl exerts its pharmacodynamic effects through a dual mechanism targeting specific neuroreceptors. It acts as a non-selective antagonist at alpha-adrenergic receptors. Binding to these receptors modulates the downstream signaling cascades, which results in the inhibition of norepinephrine-mediated vasoconstriction. This action affects vascular smooth muscle contractility across various peripheral beds.

Concurrently, Ergotyl functions as a partial agonist at 5- HT1B and 5- HT1D serotonin receptor subtypes, predominantly located on cranial blood vessels and nerve terminals. Agonism at these receptors initiates G-protein-coupled signaling pathways, leading directly to vasoconstriction of cerebral and dural arteries. This constriction alters the systemic physiological modulation of local blood flow and vascular permeability in the cranial circulation, representing the primary system-level consequence of its receptor binding profile.

Dosage and Administration Information

Administration and Dosage Specifications

The following details describe the clinical parameters for the administration of Ergotyl.


Administration Details

Administration Scope Specification
Route of Administration Oral ingestion (tablets, sublingual tablets) or injection (intramuscular [IM] or intravenous [IV]).
Dosing Schedule Oral tablets: 0.2 mg three or four times daily. Injection: 0.2 mg per dose.
Special Procedural Conditions IV administration is performed slowly over no less than 60 seconds with blood pressure monitoring. Sublingual tablets are utilized for specific indications such as migraine headaches.

Frequency and Dosage Limits

Use-Context Constraint Maximum Limits
Oral/Sublingual Use Frequency Typically administered every 6–12 hours until the condition resolves (usually 48 hours), with a lower dose if severe cramping occurs.
Oral/Sublingual Maximum Dose For sublingual use, no more than 2 tablets for any single event and no more than 5 tablets during any 7-day period.
Injection Frequency Administration of the injectable form, such as dihydroergotamine, is separated from other similar medications by at least 24 hours.

These parameters outline the documented procedural use of the drug. They define the utilized routes and the 0.2 mg dosage, while establishing frequency and cumulative dose limits over a 7-day period to characterize the course of medication use.

Recent Clinical Evidence

The research concerning Ergotyl (Ergometrine Maleate/Methylergometrine Maleate) focuses primarily on its function as a uterotonic agent, meaning its ability to promote the contraction of the uterine muscle. The evidence is derived mostly from clinical trials and systematic reviews, examining how the drug's components affect the uterus during and after childbirth. These findings contribute to the broader evidence landscape but do not provide individual predictions on how a person will respond.


Evidence for Use in Managing Acute Postpartum Bleeding (PPH)

This research was studied for its use in patients with measures related to excessive blood loss or uterine atony (lack of uterine firmness) right after delivery. Randomized controlled trials (RCTs) and meta-analyses monitored patient outcomes, including quantified measures of blood loss volume and the need for additional medical steps. Findings describe patterns observed in these studies, which have been used to contextualize whether the fixed-dose combination was associated with fewer observations of high-volume blood loss compared to patients receiving no uterotonic drug.

Evidence for Use in Preventing Postpartum Hemorrhage (PPH)

This research explored the use of the drug's components as a measure during the active management of the third stage of labor. Clinical trials examined the overall incidence of PPH and average volume of blood lost. Findings indicated that the fixed-dose combination product was observed in some studies to be associated with a lower rate of PPH incidence when compared to no intervention. Comparative evidence for using the single components alone for prevention may be limited when weighed against other standard preventative agents.

Long-term Follow-up and Duration of Effect

The research exploring this medicine largely concentrates on short-term symptom changes, with most trials involving very limited follow-up durations. Long-term effects are not fully established, and limited information is available regarding the durability of the effect or its role in uterine recovery (subinvolution) over subsequent weeks.

What Remains Uncertain About the Research

Data for certain groups, such as women with pre-existing high blood pressure or cardiac disease, remain insufficient due to their exclusion from many RCTs. The certainty remains low in some subgroup analyses. Furthermore, the comparative evidence is lacking regarding the patterns of effect of the medicine's single components when used alone. Finally, follow-up durations were limited for long-term functional recovery outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ergotyl (FAQ)

Q: What specific foods or drinks have a known interaction with Ergotyl?

Official regulatory documents explicitly state that grapefruit juice can interact with Ergotyl, potentially increasing the amount of medicine in the body. Beyond this specific mention, other general foods and drinks are not typically highlighted in the regulatory labeling as a concern.


Q: Can you take Ergotyl with common pain relievers like ibuprofen or aspirin?

Official regulatory sources do not specifically name common over-the-counter pain relievers, such as ibuprofen or aspirin, in the contraindication section for Ergotyl. However, the medicine is strictly contraindicated with strong inhibitors of the CYP 3A4 enzyme and other vasoconstrictive agents.


Q: Does drinking alcohol affect how Ergotyl works in the body?

While regulatory information does not typically list a direct chemical interaction with alcohol, patient information often advises caution with alcoholic beverages. This caution is often due to the potential for alcohol to enhance nervous system side effects like dizziness, which could affect alertness.


Q: Does Ergotyl affect sleep patterns or energy levels?

The official safety information reports nervous system effects like dizziness, confusion, and paresthesia (tingling or numbness) as possible adverse reactions. These effects are described as potentially influencing alertness or rest.


Q: Can Ergotyl be taken by people with diabetes?

Official regulatory documents note that individuals with pre-existing conditions like diabetes, high cholesterol, or obesity may have an increased risk of serious cardiovascular side effects, such as heart attack. The labeling describes this observation as a necessary precaution.


Q: Why do official documents emphasize taking Ergotyl at a certain time of day?

The medicine is prescribed according to a strict schedule, such as taking the oral tablet multiple times a day, to ensure a necessary therapeutic level of the drug is maintained in the body. This continuous presence is required to achieve the sustained uterine effect for its defined period of use.


Q: Does a missed dose of Ergotyl change the effectiveness of the drug?

Regulatory guidance for the oral form addresses the scenario of a missed dose by detailing the appropriate next step. This emphasis on maintaining the schedule indicates the importance of consistency for the medicine's expected effectiveness.


Q: Why is Ergotyl not available for purchase over the counter?

Ergotyl is classified as a prescription-only medicine due to its pharmacological actions and potential for serious adverse reactions. The risk profile, which includes conditions like vasospasm (severe blood vessel narrowing) and severe hypertension, requires professional medical assessment before and during use.


Q: Are generic versions of Ergotyl as effective as the brand name?

Regulatory agencies mandate that generic versions of a medicine must demonstrate bioequivalence to the original brand-name product. This means the generic must contain the same active ingredients and is expected to work the same way, aiming for comparable effects and safety profiles.


Q: How quickly after starting Ergotyl should a patient expect to see a positive change?

The time it takes for the medicine to begin working depends on the route of administration, according to official documents. For example, the oral tablet typically begins to act within 5 to 10 minutes, while an intravenous injection is immediate.


Q: How long does Ergotyl stay in the body after the last dose?

Studies on the drug's processing in the body show that its active component has an elimination half-life of approximately 1.9 hours. This means that about half of the medicine is removed from the bloodstream within that timeframe.


Q: Are the side effects of Ergotyl the same for every person?

Regulatory documentation lists various types of side effects, including those that are common and those that are rare. This classification confirms that the drug's effects and the experience of adverse reactions can vary significantly from one individual to the next.


Q: Do side effects from Ergotyl usually go away after the body adjusts to the medicine?

Official patient information notes that some of the common side effects that do not require medical attention are described as possibly resolving. These effects may disappear as the body adjusts to the medicine during the course of treatment.


Q: Do side effects from Ergotyl usually go away on their own?

Official patient information notes that some of the common side effects that do not require medical attention are described as possibly resolving. These effects may disappear as the body adjusts to the medicine during the course of treatment.


Q: Is Ergotyl safe for use in older patients (geriatric population)?

Official studies have not documented specific safety problems related to the elderly population. However, the product label notes the need for caution in older patients due to the natural increased likelihood of age-related heart, liver, or kidney function concerns.


Q: Is it safe to drive or operate machinery while taking Ergotyl?

Official patient information indicates that the ability to perform activities requiring high alertness, such as driving or operating machinery, may be temporarily affected. This is because possible side effects, including dizziness, lightheadedness, and confusion, could interfere with performing these tasks safely.


Q: What is the typical expected duration of treatment with Ergotyl?

The use of Ergotyl is defined in the official prescribing information as an acute, short-term treatment. For its specific obstetrical indication, the entire course of medication use is typically completed within a few days, often up to a maximum of 7 days.


Q: Is it true that Ergotyl is processed by specific enzymes in the liver?

Official drug documentation confirms that the active components are processed in the body by the CYP 3A4 enzyme system, which is a common metabolic pathway in the liver. This process is how the body breaks down and clears the medicine.


Q: What size were the patient groups in the main research studies for Ergotyl?

Clinical trials that led to the drug's regulatory review utilized varying sample sizes. For example, some key randomized studies involved patient groups of approximately 50 to 80 women per treatment group.


Q: Is Ergotyl considered a long-term or short-term treatment?

Official documentation strictly defines Ergotyl as being for acute, short-term management for its approved indication. Clinical research largely focuses on short-term effects, and the long-term safety or efficacy of the medicine is not fully established.


Q: What is the difference between a 'very common' and 'rare' side effect of Ergotyl?

Regulatory documents classify side effects by how often they are observed in studies. Generally, a 'very common' side effect is expected to occur in 1 out of 10 people or more, whereas a 'rare' effect is expected in less than 1 out of 1,000 people.


Q: Are there any specific lifestyle factors (like smoking) that may affect the action of Ergotyl?

Official regulatory warnings specifically note that tobacco smoking may enhance the vasoconstrictive effects of the medicine. This factor is highlighted in the interaction section of the official documents.

How should Ergotyl be stored and disposed of?

Storage and Disposal of Ergotyl

Ergotyl (methylergonovine maleate) must be stored strictly according to official regulatory requirements to ensure product stability.

Mandatory Storage Conditions

The medicine should be stored at room temperature in a closed container. It is essential to protect Ergotyl from heat, moisture, direct light, and freezing. Storage must be kept out of the reach of children.

Disposal Instructions

Outdated medicine or medicine that is no longer needed should not be kept. Do not dispose of this medicine through routine household disposal methods. Patients must consult a healthcare professional or pharmacist for precise instructions on how to properly dispose of any unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ergotyl found in:

A-Z Index: